Drugs / VL-2397
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03327727 | Feb 2018 → Jan 2019 | invasive aspergillosis | Vical | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VL-2397 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03327727 ↗ |
| Route | Intravenous | “600 mg IV infusion administered every day for 28 days” NCT03327727 ↗ |